Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugs, claims Roots Analysis

In recent years, the concept of STING pathway targeting therapeutics has generated a lot of enthusiasm within the medical science community. The growing popularity of this therapeutic technique has not only garnered the interest of several medical researchers (reflected in the increasing volume of scientific literature (1,000+ articles published since 2015) on this subject), but also industry stakeholders focused on drug development (evident in the growing number of clinical trials and the grants awarded for STING focused projects in the recent past).

To order this 310+ page report, which features 170+ figures and 200+ tables, please visit this link

The USD 2.8 billion (by 2030) financial opportunity within the STING pathway targeting technologies market has been analysed across the following segments:

• Types of Payment
• Upfront Payments
• Milestone Payments

• Type of STING Modulator
• Agonist
• Antagonist

• Key Therapeutic Area(s)
• Oncological Disorders
• Inflammatory Disorders
• Infectious Diseases
• Others

• Route of Administration
• Intratumoral
• Intravenous
• Oral
• Subcutaneous
• Others

• Type of Molecule
• Non-nucleotide
• Cyclic Dinucleotide
• Live Biotherapeutics
• Oncolytic Peptides
• Synthetic Peptides
• Others

• Key Geographical Regions
• North America
• Europe
• Asia-Pacific

The STING Pathway targeting Therapeutics and Technologies, 2020-2030 report features the following companies, which we identified to be key players in this domain:

• Aduro Biotech
• Bristol Myers Squibb
• Eisai
• GlaxoSmithKline
• ImmuneSensor Therapeutics
• Merck
• Noxopharm
• Spring Bank Pharmaceuticals
• Synlogic

Table of Contents

1. Preface

   2. Executive Summary

2. Introduction
3. STING Pathway Targeting Therapeutics: Current Market Landscape
4. STING Pathway Targeting Technologies: Current Market landscape
5. Company Profiles
6. Academic Grant Analysis
7. STING Related Initiatives of Big Pharmaceutical Players
8. Start-up Health Indexing
9. Publication Analysis
10. Partnerships and Collaborations

12. Funding and Investment Analysis
13. Market Sizing and Opportunity Analysis
14. Executive Insights

15. Concluding Remarks

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com